- MD, Shanghai Jiao Tong University School of Medicine, China, 1998
- Residency, Internal Medicine, Ruijin Hospital, Shanghai Jiangtong University, 2000
- Residency, Internal Medicine, Medstar Good Samaritan Hospital, 2014
- Chief Resident, Medstar Good Samaritan Hospital, 2014
- Fellowship, Cardiovascular, University of Pittsburgh, 2017
- Fellowship, Advanced Heart Failure and Transplant, University of Pittsburgh, 2018
Education & Training
Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE, Wang CR, Peter ME, Ashton-Rickardt PG. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity. 2006; 24(4): 451-61.
Zhang M, Liu N, Park SM, Wang Y, Byrne S, Murmann AE, Bahr S, Peter ME, Olson ST, Belaaouaj A, Ashton-Rickardt PG. Serine protease inhibitor 6-deficient mice have increased neutrophil immunity to Pseudomonas aeruginosa. J Immunol. 2007; 179(7): 4390-6.
Zhang M, Byrne S, Liu N, Wang Y, Oxenius A, Ashton-Rickardt PG. Differential survival of cytotoxic T cells and memory cell precursors. J Immunol. 2007; 178(6): 3483-91.
Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, Koenke T, O'Rourke B, Champion HC, Crow MT, Kass DA. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell signal. 2008; 20(12): 2231-6.
Zhang M, Takimoto E, Hsu S, Lee DI, Nagayama T, Danner T, Koitabashi N, Barth AS, Bedja D, Gabrielson KL, Wang Y, Kass DA. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol. 2010; 56(24): 2021-30.
Zhang M, Kass DA. Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci. 2011; 32(6): 360-5.
Zhang M, Takimoto E, Lee DI, Santos CX, Nakamura T, Hsu S, Jiang A, Nagayama T, Bedja D, Yuan Y, Eaton P, Shah AM, Kass DA. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation. 2012; 126(8): 942-51.
Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E, Kass DA. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015; 519(7544): 472-6.
Thapa D, Zhang M, Manning JR, Guimarães DA, Stoner MW, O'Doherty RM, Shiva S, Scott I. Acetylation of mitochondrial proteins by GCN5L1 promotes enhanced fatty acid oxidation in the heart. , Zhang M, Manning JR, Guimarães DA, Stoner MW, O'Doherty RM, Shiva S, Scott I. Am J Physiol Heart Circ Physiol. 2017; 313(2): H265-H274.
Nakamura T, Zhu G, Ranek MJ, Kokkonen-Simon K, Zhang M, Kim GE, Tsujita K, Kass DA. Prevention of PKG-1a Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation. Circ Heart Fail. 2018; 11(3)
Title: The Role of GCN5L1 Mediated Retrograde Cardiac Metabolism reprograming in heart failure development
Role: Principal Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: K08 HL157616
Start Year: 2021
End Year: 2026
